4 February 2010

Oxford BioMedica extends gene therapy collaboration in Lou Gehrig’s disease

Science|Business

Collaboration

Gene therapy specialist Oxford BioMedica plc and its partner the Amyotrophic Lateral Sclerosis (ALS) Therapy Development Institute have announced the extension of their collaboration, following successful completion of the first phase.

The extended collaboration, which is funded by the Muscular Dystrophy Association, aims to advance the development of Oxford BioMedica’s preclinical gene therapy candidate, MoNuDin, and to evaluate other gene-based strategies for the treatment of amyotrophic lateral sclerosis, or Lou Gehrig's disease.

“This collaboration adds yet another important element to our burgeoning drug development pipeline. Gene therapy is a crucial, emerging therapeutic option for diseases such as ALS and Oxford BioMedica has the...

This page requires a subscription

This page is available to subscribers only. Please log in or subscribe and plug into the Science|Buisiness Network now, to get full access to all our news, events, business opportunities and subscriber-posting service.

We are the first independent news service connecting buyers and sellers of emerging technologies, across borders and across industries. We keep you ahead of the news on early-stage R&D investment – and provide opportunities for you to find and meet new investors, licensees and development partners, through our unique Science|Business Network of leading scientific institutions including the University of Cambridge, Karolinska Institute, ETH-Zürich and Imperial College London.

Be first into the next wave of technology. Click here to learn more

Note: Log in requires cookies to be enabled on your machine.

Lost your password? Enter your email address with no password and we'll send you a new password. Use this to log in, then, if you wish, click on the 'My Details' link at the top of the page to change your password.